Rifampicin and moxifloxacin for tuberculous meningitis--authors' reply

Affiliations

¹ Department of Pharmacology and Therapy, Padjadjaran University, Hasan Sadikin Hospital, Bandung, Indonesia.
² Department of Neurology, Padjadjaran University, Hasan Sadikin Hospital, Bandung, Indonesia.
³ Department of Pharmacy, Radboud University Medical Centre, Nijmegen, Netherlands.
⁴ Department of Medicine, Radboud University Medical Centre, Nijmegen, Netherlands. Electronic address: r.vancrevel@aig.umcn.nl.

Comment

Rovina Ruslami et al. Lancet Infect Dis. 2013 Jul.

. 2013 Jul;13(7):570.

doi: 10.1016/S1473-3099(13)70156-7.

¹ Department of Pharmacology and Therapy, Padjadjaran University, Hasan Sadikin Hospital, Bandung, Indonesia.
² Department of Neurology, Padjadjaran University, Hasan Sadikin Hospital, Bandung, Indonesia.
³ Department of Pharmacy, Radboud University Medical Centre, Nijmegen, Netherlands.
⁴ Department of Medicine, Radboud University Medical Centre, Nijmegen, Netherlands. Electronic address: r.vancrevel@aig.umcn.nl.

No abstract available

Comment on

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, Borm G, Aarnoutse RE, van Crevel R. Ruslami R, et al. Lancet Infect Dis. 2013 Jan;13(1):27-35. doi: 10.1016/S1473-3099(12)70264-5. Epub 2012 Oct 25. Lancet Infect Dis. 2013. PMID: 23103177 Clinical Trial.
Rifampicin and moxifloxacin for tuberculous meningitis.
Akkerman O, Pranger A, van Altena R, van der Werf T, Alffenaar JW. Akkerman O, et al. Lancet Infect Dis. 2013 Jul;13(7):568-569. doi: 10.1016/S1473-3099(13)70101-4. Lancet Infect Dis. 2013. PMID: 23809221 No abstract available.
Rifampicin and moxifloxacin for tuberculous meningitis.
Ukwaja KN, Onyedum CC. Ukwaja KN, et al. Lancet Infect Dis. 2013 Jul;13(7):569-570. doi: 10.1016/S1473-3099(13)70099-9. Lancet Infect Dis. 2013. PMID: 23809223 No abstract available.